Navigation Links
Waters Gifts Research Equipment to University at Buffalo to Combat HIV/AIDS

MILFORD, Mass., Dec. 21, 2011 /PRNewswire/ -- At a ceremony coinciding with the 20th anniversary of Los Angeles Laker Marvin "Magic" Johnson's public revelation that he had acquired HIV, the University at Buffalo's School of Pharmacy and Pharmaceutical Sciences acknowledged Waters Corporation (NYSE: WAT) for its donation of a state-of-the-art ACQUITY® TQD System, a liquid chromatograph/mass spectrometer that will be used to build laboratory capacity and advance research into the treatment of HIV and AIDS-related illnesses in sub-Saharan Africa. The University at Buffalo is the only pharmacy school in the State University of New York System and is an internationally recognized leader in HIV Clinical Pharmacology and Therapeutics research.


The new instrument, installed within the HIV Clinical Pharmacology Laboratory, will be used to train graduate students, post-doctoral and clinical fellows in the University at Buffalo (UB)/University of Zimbabwe (UZ) AIDS International Training and Research Program (UB/AZ AITRP), a joint program managed by the UB and UZ and funded in part by the National Institutes of Health (NIH) and the Fogarty International Center.

"Our mission has been to establish a bridge between the University at Buffalo and Zimbabwe to train clinician scientists on a state-of-the-art instrumentation and grow the capacity for clinical and translational research that will impact medical care in Zimbabwe. That's why Waters donation is so important. It's a tremendous boost to the program and we're very thankful," said Dr. Gene D. Morse, Associate Director of UB's New York State Center of Excellence in Bioinformatics and Life Sciences and Professor in the School of Pharmacy and Pharmaceutical Sciences.

"Waters is honored to make a second donation of our value-added research tools to such an important international health program," said Dr. Mark Bruns, Senior Director of Waters Clinical Business Operations.  "Waters is committed to making its leading technologies accessible to researchers who can translate its power of discovery, and a deeper understanding of disease and disease management, into far-reaching impact around the globe."

The donation of equipment by Waters to the University is a continuing effort to support the UB/UZ AITRP directed by Dr. Morse in collaboration with Dr. Charles Chiedza Maponga, Director of UZ's School of Pharmacy, who also holds an academic appointment at UB.

"The UB/UZ program has been an important component in recent years in turning the destructive tide of HIV/AIDS in Zimbabwe. We have the human resources, we're getting the brick and mortar facilities … all we need now are more tools," Dr. Maponga told the audience at the ceremony.

In his remarks, Dr. James Hakim, a physician and lead medical investigator for HIV research programs in Zimbabwe recounted the dark days of the 1990's when the morbidity and mortality rate of AIDS "was a source of great anxiety and disappointment for physicians." The situation improved dramatically after the year 2000 when antiretroviral drugs came on the scene and 350,000 people in Zimbabwe entered treatment.

Commenting on the academic/industry partnership between UB, UZ and Waters Corporation, Dr. Hakim said, "As academic leaders, we play a critical role in making things happen and improving the quality of life of patients. I would like to extend my most profound gratitude to everyone involved, including Waters, for their generous support. Together, we are poised to reach even greater heights."

In 1991, when "Magic" Johnson held his press conference, AIDS was a death sentence. Very little was known about the HIV virus or how to treat patients with HIV to keep them from acquiring full-blown AIDS.

A lot has changed in 20 years.

Today, for many patients, AIDS is a manageable chronic disease but with recently appreciated long-term consequences from HIV infection and antiretroviral adverse effects, remains an active and growing research field. Research has led to new medications, new treatment regimens and new diagnostic tests that now prolong the lives of hundreds of thousands of patients.

For many developing regions of the world, including sub-Saharan Africa, the picture, while improving, is still bleak. Dr. Maponga says he is determined to give hope to ailing patients in his homeland and those in nearby countries by building bridges between Zimbabwe and developed countries like the U.S. and by adopting methods that they have used to control their AIDS epidemics. "We'll accomplish this with drug manufacturing and distribution, adherence programs, pharmacological research, education and training. And we continue to make steady progress in attaining these goals."

About the University at Buffalo – University of Zimbabwe AIDS International Training and Research Program

Initiated in the spring of 2009, The University at Buffalo (UB) and University of Zimbabwe (UZ) AIDS International Training and Research Program is a postgraduate fellowship training initiative to support HIV/AIDS clinical and translational pharmacology research in southern African countries. The UB and UZ faculty provide mentored training with a focus on current and investigational drug treatment for HIV/AIDS and tuberculosis, as well as the expertise in clinical pharmacology, which integrates multidisciplinary teams to achieve the HIV/AIDS research goals for Zimbabwe and other southern African countries and build research capacity. Key programmatic areas include pharmacokinetics and pharmacodynamics, with newly emerging research components that include genomics, healthcare informatics, economics and outcomes and nanomedicine. Implementation research initiatives include medication adherence, drug interactions, traditional medicine use, bioequivalence testing, clinical pharmacology laboratory sciences, integration of therapeutic drug monitoring and viral load and resistance tests, and biochemical and clinical adverse effect monitoring.

About Waters Corporation (

For more than 50 years, Waters Corporation (NYSE: WAT) has created business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide.

Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.

With revenue of $1.64 billion in 2010 and 5,400 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.

Waters and ACQUITY TQD are trademarks of Waters Corporation.



SOURCE Waters Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Waters Recognizes the Dr. Ganesh Anand Laboratory at the National University of Singapore as Center of Innovation
2. Waters Introduces New TruView LCMS Certified Vials for the Analytical Laboratory
3. Waters Showcases ACQUITY UltraPerformance LC and Mass Spectrometry (UPLC/MS) Tools for Increasing Laboratory Efficiency at the American Association for Clinical Chemistry Annual Meeting
4. Waters CE Marks In Vitro Diagnostic MassTrak Immunosuppressants XE Kit
5. Waters Introduces Ostro Sample Preparation Products
6. Waters Expands Xevo MS Instrument Platform With Next-Generation Mass Spectrometers
7. Waters Corporation and NIBRT Partner to Bring Greater Control and Predictability to Biopharmaceutical Processing
8. Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard
9. New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals
10. Paper or Plastic? Technology Fuels Gift Card Popularity and Access as an Alternative to Cash Incentives and Gifts
11. Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice President of Research & Development
Post Your Comments:
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):